<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03226431</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00080819</org_study_id>
    <nct_id>NCT03226431</nct_id>
  </id_info>
  <brief_title>Use of ARINA-1 in an Intermediate Size Patient Population of Bilateral Lung Transplant Patients With CLAD Grade 0</brief_title>
  <acronym>ARINA-1</acronym>
  <official_title>Use of ARINA-1 in an Intermediate Size Patient Population of Bilateral Lung Transplant Patients With CLAD Grade 0 at Duke University to Improve FEV1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To treat an intermediate size patient population of bilateral lung transplant patients with
      CLAD-0.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To treat an intermediate size patient population of bilateral lung transplant patients with
      CLAD-0. Treating physicians will follow standard of care for patients and monitor pulmonary
      function, fractional exhaled nitric oxide and quality of life of the patients.

      Patient safety will be monitored by assessing changes in these parameters, as well as changes
      in standard of care measurements (e.g., laboratory values and x-ray images).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 11, 2017</start_date>
  <completion_date type="Actual">June 25, 2019</completion_date>
  <primary_completion_date type="Actual">June 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in FEV1</measure>
    <time_frame>Baseline, 1 month, 3 months, 6 months, 12 months</time_frame>
    <description>Each individual's changes in pulmonary function will be assessed using the linear slope of FEV1 change from enrollment to the end of the treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in FENO</measure>
    <time_frame>Baseline</time_frame>
    <description>Each individual's changes in FENO will be assessed using the change in mean baseline FENO measurements to the mean measurements post-ARINA-1 use.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Quality of Life</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Patient-reported quality of life measures assessed pre- and post-ARINA-1 will be compared for each participant.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Lung Transplant</condition>
  <arm_group>
    <arm_group_label>ARINA-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascorbic acid (ARINA-1) (inhaled ascorbic acid 88 mg/ml) will be nebulized twice daily for 3 months using a PARI eFlow nebulizer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>ARINA-1 (inhaled ascorbic acid 88 mg/ml) will be nebulized twice daily for 3 months using a PARI eFlow nebulizer</description>
    <arm_group_label>ARINA-1</arm_group_label>
    <other_name>ARINA-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. &gt;6 months post-bilateral lung transplant

          2. Any patient with a stable FEV1 or a decline that is &lt; 20% from baseline.

          3. No current signs of infection

          4. No current signs of rejection

          5. &gt;21 years old

          6. Routinely followed at the enrolling site

          7. Capable of giving informed consent

        Exclusion Criteria:

          1. Interstitial or peribronchial/peribronchiolar fibrosis on transbronchial biopsy

          2. Evidence of active congestive heart failure or symptomatic coronary artery disease, in
             the opinion of the site investigator

          3. CLAD grade 1 or higher

          4. Currently on any ICS therapy

          5. Initiation of chronic azithromycin within 1 month of study enrollment (chronic
             azithromycin use defined as azithromycin 250mg or 500mg daily or every Monday,
             Wednesday, Friday)

          6. Positive pregnancy test at screening, if female and of child bearing potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omar Mohamedaly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lorenzo Zaffiri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>July 14, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>July 3, 2019</last_update_submitted>
  <last_update_submitted_qc>July 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

